07.13.20

EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officer

Source: EyePoint Pharmaceuticals

EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-related macular degeneration (AMD) and new pipeline expansion opportunities under evaluation.

In conjunction with this appointment, Dr. Duker has stepped down from the company’s Board of Directors after 4 years of service to focus on this newly created role. Dr. Duker will serve in this role on a part time basis while continuing his ongoing retinal practice and serving as the Chair of Ophthalmology at Tufts Medical Center and the Tufts University School of Medicine.  

“Dr. Jay Duker is an ophthalmology pioneer and highly regarded retinal disease expert. We are delighted to have Jay join our executive team as our Chief Strategic Scientific Officer bringing his world class experience as a retinal specialist to EYP-1901, our lead development candidate that we believe can alter the treatment paradigm for wet AMD, as this important program progresses toward the clinic,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “Jay’s extensive experience treating and leading research efforts for retinal diseases will also be extremely beneficial as we look to expand our ocular disease pipeline by leveraging the extended delivery capability of our two technology platforms, Durasert and Verisome, as well as assessing additional in-licensing opportunities.”

“I am very excited about the potential for EYP-1901 as a single injection 6-month treatment option to provide a long-lasting, effective, safe and convenient therapy for wet AMD patients,” said Dr. Duker. “I look forward to leading EyePoint’s efforts to drive EYP-1901 toward the clinic as we prepare for an investigational new drug (IND) application later this year followed quickly by the initiation of a phase 1 trial. I expect that EYP-1901 represents the first in a series of potential new pipeline programs using our Durasert and Verisome technologies, and I am excited to help lead the evaluation and implementation of these programs.”

 

Related Content